Tianjin Chase Sun PharmaceuticalLtd Toekomstige groei

Future criteriumcontroles 3/6

Tianjin Chase Sun PharmaceuticalLtd zal naar verwachting groeien in winst en omzet met respectievelijk 34.4% en 8.9% per jaar. De winst per aandeel zal naar verwachting groeien met 33% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.3% zijn.

Belangrijke informatie

34.4%

Groei van de winst

33.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	19.0%
Inkomstengroei	8.9%
Toekomstig rendement op eigen vermogen	6.3%
Dekking van analisten	Low
Laatst bijgewerkt	17 May 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

Nov 22

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Nov 01

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Sep 26

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Aug 02

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Jun 12

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

May 22

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

May 21

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 04

Winst- en omzetgroeiprognoses

SZSE:300026 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	7,083	664	N/A	629	1
12/31/2025	6,511	557	N/A	431	1
12/31/2024	6,194	533	N/A	715	1
9/30/2024	5,627	166	738	1,043	N/A
6/30/2024	5,682	309	1,102	1,417	N/A
3/31/2024	5,913	389	980	1,309	N/A
12/31/2023	6,109	507	1,183	1,530	N/A
9/30/2023	6,672	663	1,112	1,485	N/A
6/30/2023	6,762	617	382	911	N/A
3/31/2023	6,577	561	269	928	N/A
1/1/2023	6,650	624	-25	745	N/A
9/30/2022	7,084	521	-538	262	N/A
6/30/2022	7,496	602	-258	497	N/A
3/31/2022	7,764	732	-317	418	N/A
12/31/2021	7,671	687	-286	392	N/A
9/30/2021	7,266	611	111	717	N/A
6/30/2021	7,192	667	-173	395	N/A
3/31/2021	7,001	657	-162	364	N/A
12/31/2020	6,488	573	-367	197	N/A
9/30/2020	6,109	485	-753	-148	N/A
6/30/2020	5,497	396	-563	100	N/A
3/31/2020	5,085	337	-519	149	N/A
12/31/2019	5,003	403	-375	216	N/A
9/30/2019	4,796	264	-221	247	N/A
6/30/2019	4,548	216	-253	147	N/A
3/31/2019	4,303	219	-101	225	N/A
12/31/2018	4,224	211	93	388	N/A
9/30/2018	4,015	463	297	593	N/A
6/30/2018	3,894	514	N/A	805	N/A
3/31/2018	3,605	485	N/A	865	N/A
12/31/2017	3,374	451	N/A	742	N/A
9/30/2017	3,543	633	N/A	610	N/A
6/30/2017	3,564	630	N/A	590	N/A
3/31/2017	3,743	666	N/A	472	N/A
12/31/2016	3,867	659	N/A	448	N/A
9/30/2016	3,722	582	N/A	362	N/A
6/30/2016	3,635	599	N/A	251	N/A
3/31/2016	3,596	572	N/A	108	N/A
12/31/2015	3,348	535	N/A	121	N/A
9/30/2015	3,187	541	N/A	193	N/A
6/30/2015	3,076	474	N/A	115	N/A
3/31/2015	2,969	452	N/A	220	N/A
12/31/2014	2,864	447	N/A	150	N/A
9/30/2014	2,681	421	N/A	105	N/A
6/30/2014	2,405	395	N/A	110	N/A
3/31/2014	2,201	362	N/A	93	N/A
12/31/2013	2,097	340	N/A	144	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 300026 ( 34.4% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 300026 ( 34.4% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 300026 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 300026 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.8% per jaar).

Hoge groei-inkomsten: De omzet van 300026 ( 8.9% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 300026 zal naar verwachting over 3 jaar laag zijn ( 6.3 %).

Tianjin Chase Sun PharmaceuticalLtd Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Seems To Use Debt Quite Sensibly

We Think That There Are More Issues For Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Than Just Sluggish Earnings

Third quarter 2024 earnings released: EPS: CN¥0.008 (vs CN¥0.051 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 15%

Investors Appear Satisfied With Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Prospects

Second quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.06 in 2Q 2023)

These 4 Measures Indicate That Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Is Using Debt Reasonably Well

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

There's No Escaping Tianjin Chase Sun Pharmaceutical Co.,Ltd's (SZSE:300026) Muted Earnings

Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026) Has Announced A Dividend Of CN¥0.03

This Broker Just Slashed Their Tianjin Chase Sun Pharmaceutical Co.,Ltd (SZSE:300026) Earnings Forecasts

Dividend of CN¥0.03 announced

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.06 in 1Q 2023)

Tianjin Chase Sun PharmaceuticalLtd's (SZSE:300026) Sluggish Earnings Might Be Just The Beginning Of Its Problems

New minor risk - Earnings quality

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2024

Full year 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.21 in FY 2022)

Investor sentiment deteriorates as stock falls 16%

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.051 (vs CN¥0.04 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.06 (vs CN¥0.039 in 2Q 2022)

Tianjin Chase Sun Pharmaceutical Co.,Ltd. Approves Final Cash Dividend for A Shares for the Year 2022, Payable on 12 May 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.04 (vs CN¥0.061 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.093 in 2Q 2021)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces Final Cash Dividend on A Shares for the Year 2021, Payable on May 19, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Profit Distribution Proposal for 2021

Investor sentiment deteriorated over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 21, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Tianjin Chase Sun Pharmaceutical Co.,Ltd Proposes Cash Dividend for 2021

Investor sentiment improved over the past week

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.061 (vs CN¥0.09 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.093 (vs CN¥0.067 in 2Q 2020)

Investor sentiment improved over the past week

Tianjin Chase Sun Pharmaceutical Co.,Ltd Approves Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.06 (vs CN¥0.04 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.19 (vs CN¥0.14 in FY 2019)

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day low: CN¥4.07

New 90-day low: CN¥4.26

New 90-day low: CN¥4.52

New 90-day low: CN¥5.01

Tianjin Chase Sun Pharmaceutical Co.,Ltd Announces the Election of Li Li as an Independent Director

New 90-day low: CN¥5.27

Third quarter earnings released

New 90-day high - CN¥6.45

Earnings released

Tianjin Chase Sun Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 25, 2020

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven